<DOC>
	<DOCNO>NCT02759952</DOCNO>
	<brief_summary>Mutations PDE6A gene - encode -subunit rod cGMP-phosphodiesterase - account 1 % autosomal recessive retinitis pigmentosa ( arRP ) impair regulation cGMP level rod outer segment . This study aim detailed clinical characterization patient PDE6A mutation preparation clinical gene replacement study ( phase I/II safety trial ) .</brief_summary>
	<brief_title>Clinical Characterization PDE6A-related Retinitis Pigmentosa Preparation Gene Therapy Trial</brief_title>
	<detailed_description>Retinitis pigmentosa ( RP ) clinically genetically heterogenous group hereditary retinal disorder , one common type retinal degeneration prevalence 1:4000 . More 45 gene associate RP far , whose defect cause progressive loss rod photoreceptor function , follow cone photoreceptor dysfunction often leading complete blindness . Mutations PDE6A gene - encode -subunit rod cGMP-phosphodiesterase - account 1 % autosomal recessive retinitis pigmentosa ( arRP ) impair regulation cGMP level rod outer segment . With help improve genetic functional diagnostic tool early recognition differentiation become possible . Still , date establish therapy available , therefore , social professional consequence essential task deal . The modern ophthalmological functional diagnostic tool enable precise characterisation early recognition retinal disease . The detailed result information help extend understanding pathological mechanism involve disease . In study investigator intend investigate patient genetically confirm diagnosis Retinitis pigmentosa due PDE6A mutation hereby assess function structure retina extensive battery test .</detailed_description>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>Retinitis pigmentosa patient genetically confirm mutation PDE6Agene write informed consent severe general disease , would make long examination possible patient give write informed consent independently</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>retinitis pigmentosa</keyword>
	<keyword>PDE6A</keyword>
	<keyword>gene therapy trial</keyword>
</DOC>